Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2025Thrombosis and Haemostasis

Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets

View Full Paper
Ask AI
Bookmark
Share

Authors

SZSiyue ZhengSLShuang LiuYSYan Shen

Discussion

Loading...

Member takes

Overview

In vitro and in vivo analysis demonstrated that medical compounds C109 and C116 inhibit thrombosis, suggesting improved safety profiles in antithrombotic therapy.

Key Points

  • C109 and C116 effectively inhibit thrombosis at levels comparable to existing antithrombotic agents, without increasing bleeding risk.
  • In vitro and in vivo evaluations showed that these compounds suppressed arterial and venous thrombogenesis efficiently.
  • Targeting the β3/Src interaction offers a promising therapeutic strategy for managing thrombosis while preserving hemostatic function.
  • C109's favorable pharmacokinetic properties highlight its potential for further clinical development and application.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/68ece2abd1bb2827d12973f1https://doi.org/10.1055/a-2706-9879
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy2026
  2. 2Is dual targeting of FXII and Gas6 a good strategy to prevent thrombosis with no risks of bleeding?2025
  3. 3Artificial platelets suppressing deep vein thrombosis via competitive adhesion2026
  4. 4Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties2025 · 8 citations
  5. 5Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders.2025